Expertise in
39
conditions

Dr. Herbert A. Eradat

Internal Medicine
Office
200 Medical Plz Ste 120, 
Los Angeles, CA 
Offers Telehealth
Expertise in
39
conditions
Office
200 Medical Plz Ste 120, 
Los Angeles, CA 

Overview

Herbert Eradat is a primary care provider, practicing in Internal Medicine in Los Angeles, California.

Dr. Eradat is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Mycosis Fungoides, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 7 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Office
200 Medical Plz Ste 120, Los Angeles, CA 90095
Other Locations
Premiere Oncology A Medical Corporation
2020 Santa Monica Blvd Ste 600, Santa Monica, CA 90404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Biological
Study Drug: Lisocabtagene maraleucel
Study Phase: Phase 2
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

28 Total Publications

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.
Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.
Journal: Blood neoplasia
Published: March 20, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine
Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (0.5 miles away)
310-794-9718
Languages Spoken:
English

Charles Bernstein is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Bernstein is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

Expertise in
15
conditions
Dr. Mario F. Mendez
Internal Medicine
Expertise in
15
conditions
Dr. Mario F. Mendez
Internal Medicine

Office

300 Medical Plz Ste B200, 
Los Angeles, CA 
 (0.1 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mario Mendez is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Mendez is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Frontotemporal Dementia, Dementia, Alzheimer's Disease, and Developmental Dysphasia Familial.

Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine
Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (3.6 miles away)
310-423-5161
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Albert is a primary care provider, practicing in Internal Medicine in West Hollywood, California. He has been practicing medicine for over 10 years. Dr. Albert is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Nijmegen Breakage Syndrome, Wiskott-Aldrich Syndrome, Autosomal Dominant Hyper IgE Syndrome, Splenectomy, and Spinal Fusion. Dr. Albert is currently accepting new patients.

Frequently Asked Questions about Dr. Herbert A. Eradat

How do I make an appointment with Dr. Herbert A. Eradat?

You can book an appointment with Dr. Herbert A. Eradat by calling their office at 310-206-6909. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Herbert A. Eradat a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Herbert A. Eradat is classified as an Elite expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Herbert A. Eradat specialize in?

While Dr. Herbert A. Eradat is a Internal Medicine, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Mycosis Fungoides. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Herbert A. Eradat participate in research or clinical trials?

Yes. Dr. Herbert A. Eradat has published 28 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Herbert A. Eradat's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Herbert A. Eradat accept my insurance?

Dr. Herbert A. Eradat accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-206-6909 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eradat's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 19 Advanced Conditions
View All 95 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile